Organization (Academic)
Charles Drew University of Medicine and Science
ClinicalTrials.gov lists Charles Drew University of Medicine and Science as lead sponsor of 43 trials. It has 7 active development programs and 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Charles Drew University of Medicine and Science: 43 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (46)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 10 |
| Diabetes Mellitus, Type 2 | 6 |
| Obesity | 5 |
| Insulin Resistance | 4 |
| COVID-19 | 3 |
Showing 5 of 46 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Mifepristone 600 mg daily | Diabetes Mellitus | Phase 2 | 1 |
| Mifepristone 600 mg daily | Diabetes Mellitus, Type 2 | Phase 2 | 1 |
| Mifepristone 600 mg daily | Insulin Resistance | Phase 2 | 1 |
| green tea and quercetin + docetaxel | Prostatic Neoplasms | Phase 1/2 | 1 |
| Intervention Group | Diabetes Mellitus | Not reported | 1 |
Showing 5 of 7 active programs.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Transdermal Testosterone gel | 1 |
| 3 - NPH insulin QHS | 1 |
| 1- Insulin glargine QHS | 1 |
| NPH twice-daily | 1 |
| Insulin glargine at bedtime instead of NPH | 1 |
Showing 5 of 15 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 17% hit target (n=18) | 22% on time (n=9) |
Journals published in (41)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 3 |
| Archives of sexual behavior | 3 |
| American journal of lifestyle medicine | 2 |
| American journal of public health | 2 |
| Diabetes care | 2 |
Showing 5 of 41 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7 | 2 | 2023-09-26 |
Organization relationships (8)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 2 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Friends Research Institute | Co sponsors trial with | 1 |
| University of Southern California | Co sponsors trial with | 1 |
| The 108 Military Central Hospital | Co sponsors trial with | 1 |
Showing 5 of 8 relationships.
Latest dated events (62)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 62 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE | Certificate of waiver | Active |
Biomarker capability evidence (81)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
| FAH | Trial sponsor | Named in trial inclusion criteria |
| GNRH1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 81 evidence rows.
Biomarkers this organization publishes on (39)
Shown in this order: most publications first.
Showing 5 of 39 biomarkers.
On Scientist.com
Charles Drew University of Medicine and Science is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Charles Drew University of Medicine and Science on Scientist.com
For prices, more details, or to contact Charles Drew University of Medicine and Science, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.